论文部分内容阅读
我院自1995年3月至2000年3月,应用HCPT与白细胞介素—2(IL—2)联合用以膀胱腔内灌注预防膀胱癌术后复发,取得良好疗效,报告如下: 1 临床资料与方法 膀胱癌50例,男39例,女11例,年龄29～70岁,膀胱部分切除32例。TURBt8例,肿瘤单纯切除10例。术后病理检查均为膀胱移行上皮细胞癌其中Ta3例。T_1 34例,T_26例,T_37例。随机分为HCPT+IL—2组和HCPT组,每组25例。IL—2由北京瑞得合通药业有限公司提供。每支含IL—2
Our hospital from March 1995 to March 2000, the application of HCPT and interleukin-2 (IL-2) in combination with intravesical instillation of bladder cancer prevention of recurrence of bladder cancer, and achieved good results, the report is as follows: 1 Clinical data Methods 50 cases of bladder cancer, 39 males and 11 females, aged 29 to 70 years, partial resection of the bladder in 32 cases. TURBt8 cases, simple excision of the tumor in 10 cases. Postoperative pathological examination of bladder transitional cell carcinoma in which Ta3 cases. T_1 34 cases, T_26 cases, T_37 cases. Randomly divided into HCPT + IL-2 group and HCPT group, 25 cases in each group. IL-2 is provided by Beijing Ruide Pharmaceutical Co., Ltd. Each contains IL-2